ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2826

Performance Of Five Current Risk Algorithms In Predicting Cardiovascular Events In Rheumatoid Arthritis Patients

Elke.E.A. Arts1, Calin Popa1, Alfons A. den Broeder2, Anne G. Semb3, Tracey Toms4, George Kitas4, Piet L.C.M. van Riel1 and Jaap Fransen5, 1Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 3Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, United Kingdom, 5Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cardiovascular risk in rheumatoid arthritis (RA) is increased. The cardiovascular (CV) risk algorithms used in the general population may underestimate the risk of cardiovascular disease (CVD) in the RA population1. This study was undertaken to assess the predictive ability of 5 established CV risk models for the 10-year risk of fatal and non-fatal CVD in European patients with Rheumatoid Arthritis.

Methods: Included were the Framingham risk score (FRS), the Systematic Coronary Risk Evaluation score (SCORE), the modified SCORE according to the EULAR recommendations for CV risk2 (M-SCORE), the Reynolds risk score (RRS) and the QRisk II risk score. Prospectively collected data from the Nijmegen early RA inception cohort were used. Patients with CVD prior to enrollment were excluded. Discriminatory ability for CV risk prediction was estimated by the area under the receiver operating characteristic (ROC) curve. Calibration was assessed by comparing the observed versus expected number of events using Hosmer-Lemeshov tests and calibration plots. Sensitivity and specificity were calculated for the cut-off values of 10% and 20% predicted risk.

Results: In total, n=1050 patients were included. During follow-up, 145 patients developed a CV event. The mean±SD age was 54±13.8 years, 66% were female and 74%  were rheumatoid factor positive. Areas under the ROC curve were 0.75 (95% CI; 0.71-0.80), 0.75 (95% CI;0.71-0.80), 0.76 (95% CI; 0.73-0.80), 0.75 (95% CI; 0.71-0.79) and 0.77(95% CI; 0.73-0.80) for the SCORE, M-SCORE, FRS, Reynolds and QRisk II respectively, indicating moderate to good discrimination between patients with and without a CV event. All five models underestimated CV risk at low and middle observed risk levels, and overestimated CV risk at high observed risk levels (fig.1). For the 10% and 20% cut-off values used as indicators for CV preventive treatment, sensitivity ranged from 66-87% and 43-67% respectively and specificity ranged from 44-57% and 67-81% respectively. Depending on the model, 13% to 35% of observed CV events occurred in RA patients who were classified as low risk (<10%) for CVD.

Conclusion: Established risk models generally underestimate CV risk in RA patients. There is an unmet Mono Image_Figure2.JPGneed for development of a RA-specific CV risk model.

Figure 2. Observed (closed bars) versus predicted (open bars) CV event rate (%) in deciles of predicted risk, for the SCORE (A), M-SCORE (B), FRS (C),Reynolds (D) and QRisk II (E) risk algorithms.

References

1       Crowson CS, Matteson EL, Roger VL, et al. Usefulness of Risk Scores to Estimate the Risk of Cardiovascular Disease in Patients With Rheumatoid Arthritis. Am J Cardiol. 2012;10:420-24.

2        Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31.

 


Disclosure:

E. E. A. Arts,
None;

C. Popa,
None;

A. A. den Broeder,
None;

A. G. Semb,

Merck/Schering-Plough, Abbott, BMS, Pfizer/Wyeth, Genentech and Roche,

5;

T. Toms,
None;

G. Kitas,
None;

P. L. C. M. van Riel,
None;

J. Fransen,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-five-current-risk-algorithms-in-predicting-cardiovascular-events-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology